公开(公告)号：EP1910523A1

公开(公告)日：2008-04-16

申请号：EP06752619.4

申请日：2006-06-21

申请人： MEDVET SCIENCE PTY. LTD.

发明人： XIA, Pu ,  SUKOCHEVA, Olga ,  VADAS, Mathew, Alexander

IPC分类号： C12N9/00 ,  A61K48/00 ,  C12N9/99 ,  A61P35/00

CPC分类号： C12N15/1137 ,  A61K48/00 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/3517 ,  C12Y207/01091

摘要： The present invention relates generally to a method of modulating EGFR-mediated cellular functional activity and agents useful for same. More particularly, the present invention relates to a method of modulating agonist induced EGFR-mediated cellular proliferation by modulating upstream intracellular sphingosine kinase signalling. The method of the invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant EGFR-mediated cellular functioning, in particular aberrant EGFR-mediated cellular proliferation.

公开(公告)号：EP1804800A4

公开(公告)日：2008-03-19

申请号：EP05793868

申请日：2005-10-17

申请人： MEDVET SCIENCE PTY LTD

发明人： DEWAR ANDREA LOUIS ,  HUGHES TIMOTHY PETER ,  LYONS ALAN BRUCE

IPC分类号： A61K31/506 ,  A61P25/28 ,  A61P35/00

CPC分类号： A61K31/506

公开(公告)号：EP1804800A1

公开(公告)日：2007-07-11

申请号：EP05793868.0

申请日：2005-10-17

申请人： MEDVET SCIENCE PTY. LTD.

发明人： DEWAR, Andrea, Louis ,  HUGHES, Timothy, Peter ,  LYONS, Alan, Bruce

IPC分类号： A61K31/506 ,  A61P25/28 ,  A61P35/00

CPC分类号： A61K31/506

摘要： This invention relates to the use of 4-(4-methylpiperazin-l-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2- ylamino)phenyl]-benzamide, (also known as imatinib, gleevec, glivec, cgp57148b or 8TI571), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of c-fms associated diseases including; choriocarcinoma, malignant histiocytosis, embryonal carcinoma, endometrial carcinoma, brain microglial tumours, sarcoidosis, microglial cell involvement in normal and variant Creutzfeld- Jacob disease, and amyotrophic lateral sclerosis.

公开(公告)号：EP1682571A4

公开(公告)日：2006-12-06

申请号：EP04789620

申请日：2004-10-27

申请人： MEDVET SCIENCE PTY LTD

发明人： GUTHRIDGE MARK ,  RAMSHAW HAYLEY ,  STOMSKI FRANK ,  FELQUER FERNANDO ,  LOPEZ ANGEL

IPC分类号： C07K2/00 ,  A61K38/00 ,  A61K38/19 ,  A61K38/20 ,  A61P35/00 ,  A61P43/00 ,  C07K7/00 ,  C07K7/04 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/71 ,  C07K14/715

CPC分类号： C07K14/435 ,  A61K38/00 ,  C07K14/715 ,  C07K14/7153

摘要： The present invention relates to a novel bidentate motif that is composed of two adjacent residues of tyrosine and serine which have been found to be involved in the binding of crucial cytoplasmic proteins which are involved in cell signalling pathways. In some cases, the cytoplasmic proteins are ubiquitous proteins involved in cell signalling pathways that may include mitogenesis, transformation and survival. The bidentate motif may have a sequence alignment N-X-X-Y- (X) 1-13-[R/K/H/Q]-[X/Psi] 2-3-S/T-X-P; Y- (X) 1-16-[R/K/H/Q]-[X/Psi] 2-3-S/T-X-P; or N-X-X-Y-[X]1-30-[R/K/Q/H]-[X]1-4-[S/T]-X-p wherein X is any residue, Y is tyrosine, S/T is serine or threonine and Y is a hydrophibic residue or an equivalent thereof. Preferably the residues are Tyr577 and Ser585 of the common ßc of the GM-CSF/IL-5/IL-3 receptor.

公开(公告)号：EP1682570A4

公开(公告)日：2006-12-06

申请号：EP04789618

申请日：2004-10-27

申请人： MEDVET SCIENCE PTY LTD

发明人： GUTHRIDGE MARK ,  RAMSHAW HAYLEY ,  STOMSKI FRANK ,  LOPEZ ANGEL

IPC分类号： C07K2/00 ,  A61K38/00 ,  A61K38/19 ,  A61K38/20 ,  A61P35/00 ,  A61P43/00 ,  C07K5/113 ,  C07K7/06 ,  C07K14/435 ,  C07K14/71 ,  C07K14/715

CPC分类号： C07K5/1021 ,  A61K38/00 ,  C07K14/435 ,  C07K14/715 ,  C07K14/7153

摘要： The present invention relates to a binding motif and methods of regulating cell function which methods target a single amino acid residue preferably a Tyr in a binding motif equivalent to a motif of the common beta chain (ßc) of the GM-CSF/IL-3/IL-5 receptor. Preferably, the cell functions affect cell survival and proliferation in cells. The methods can be used for treatments of conditions relating to cell survival and proliferation and can be used to expand progenitor cells, for instance, for transplantation purposes.

摘要翻译： 本发明涉及调节细胞功能的结合基序和方法，所述方法靶向与GM-CSF / IL-3的普通β链基序（ßc）相当的结合基序中的单个氨基酸残基，优选Tyr / IL-5受体。 优选地，细胞功能影响细胞的细胞存活和增殖。 该方法可以用于治疗与细胞存活和增殖相关的病症，并且可以用于扩增祖细胞，例如用于移植目的。

公开(公告)号：EP1613765A4

公开(公告)日：2006-08-09

申请号：EP04721434

申请日：2004-03-18

申请人： MEDVET SCIENCE PTY LTD

发明人： PITSON STUART M ,  BOLZ STEFFEN-SEBASTIAN

IPC分类号： C12Q1/48 ,  G01N33/68

CPC分类号： C12Q1/485 ,  G01N33/6887 ,  G01N2800/322

公开(公告)号：EP1682571A1

公开(公告)日：2006-07-26

申请号：EP04789620.4

申请日：2004-10-27

申请人： MEDVET SCIENCE PTY. LTD.

发明人： GUTHRIDGE, Mark ,  RAMSHAW, Hayley ,  STOMSKI, Frank ,  FELQUER, Fernando ,  LOPEZ, Angel

IPC分类号： C07K2/00 ,  C07K7/00 ,  C07K7/04 ,  C07K7/06 ,  C07K7/08 ,  C07K14/71 ,  C07K14/715 ,  A61K38/19 ,  A61K38/20 ,  A61P35/00 ,  A61P43/00

CPC分类号： C07K14/435 ,  A61K38/00 ,  C07K14/715 ,  C07K14/7153

摘要： The present invention relates to a novel bidentate motif that is composed of two adjacent residues of tyrosine and serine which have been found to be involved in the binding of crucial cytoplasmic proteins which are involved in cell signalling pathways. In some cases, the cytoplasmic proteins are ubiquitous proteins involved in cell signalling pathways that may include mitogenesis, transformation and survival. The bidentate motif may have a sequence alignment N-X-X-Y- (X) 1-13-[R/K/H/Q]-[X/Ψ] 2-3-S/T-X-P; Y- (X) 1-16-[R/K/H/Q]-[X/Ψ] 2-3-S/T-X-P; or N-X-X-Y-[X]1-30-[R/K/Q/H]-[X]1-4-[S/T]-X-p wherein X is any residue, Y is tyrosine, S/T is serine or threonine and Y is a hydrophibic residue or an equivalent thereof. Preferably the residues are Tyr577 and Ser585 of the common ßc of the GM-CSF/IL-5/IL-3 receptor.

公开(公告)号：EP1499343A4

公开(公告)日：2005-12-28

申请号：EP03745226

申请日：2003-03-28

申请人： MEDVET SCIENCE PTY LTD

发明人： PITSON STUART M ,  XIA PU ,  MORETTI PAUL A ,  ZEBOL JULIA R ,  VADAS MATHEW A ,  WATTENBERG BRIAN W

IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/18 ,  A61K38/19 ,  A61K38/43 ,  A61K45/00 ,  A61P1/04 ,  A61P9/10 ,  A61P11/06 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/06 ,  A61P43/00 ,  C07K16/40 ,  C12N9/12

CPC分类号： C07K16/40

公开(公告)号：EP1558736A1

公开(公告)日：2005-08-03

申请号：EP03750156.6

申请日：2003-10-14

申请人： MEDVET SCIENCE PTY. LTD.

发明人： GAMBLE, Jennifer, Ruth ,  VADAS, Mathew ,  PITSON, Stuart ,  XIA, Pu ,  LIMAYE, Vidya

IPC分类号： C12N15/12 ,  C12N15/63 ,  C12N5/16 ,  A61K48/00 ,  A61K38/45

CPC分类号： C12N9/1205 ,  A61K38/45 ,  C12N2799/022

摘要： The present invention relates generally to a method of modulating endothelial cell functional characteristics and to agents useful for same. More particularly, the present invention relates to a method of modulating vascular endothelial cell pro-inflammatory and angiogenic phenotypes by modulating the functional levels of intracellular sphingosine kinase. The method of the present invention is useful, inter alia, in relation to the treatment and/or prophylaxis of conditions which are characterised by inadequate endothelial cell functioning and may include conditions such as vascular engraftment, organ transplantation or wound healing or conditions which are characterised by an aberrant endothelial cell inflammatory or angiogenic phenotype. Further, the method of the present invention facilitates the development of agents, such as functionally manipulated endothelial cell populations, for a range of therapeutic and/or prophylactic uses.

公开(公告)号：EP1499343A1

公开(公告)日：2005-01-26

申请号：EP03745226.5

申请日：2003-03-28

申请人： MEDVET SCIENCE PTY. LTD.

发明人： PITSON, Stuart M. ,  XIA, Pu ,  MORETTI, Paul, A. ,  VERWEY, Julia R. ,  VADAS, Mathew A. ,  WATTENBERG, Brian W.

IPC分类号： A61K38/43 ,  A61K38/18 ,  A61K38/19 ,  A61K38/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07K16/40

摘要： The present invention relates generally to a method of modulating cellular activity and to agents for use therein. More particularly, the present invention provides a method of modulating cellular activity by modulating phosphorylation of sphingosine kinase and, thereby, its activation. In a related aspect, the present invention provides a method of modulating sphingosine kinase functional activity via modulation of its phosphorylation and agents for use therein. The present invention still further extends to sphingosine kinase variants and to functional derivatives, homologues or analogues, chemical equivalents and mimetics thereof exhibiting reduced and/or ablated capacity to undergo phosphorylation. The method and molecules of the present invention are useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate cellular and/or sphingosine kinase functional activity. The present invention is further directed to methods for identifying and/or designing agents capable of modulating sphingosine kinase phosphorylation.